Stavros G Memtsoudis1, Megan Fiasconaro2, Ellen M Soffin2, Jiabin Liu2, Lauren A Wilson2, Jashvant Poeran3, Janis Bekeris4, Henrik Kehlet5. 1. Department of Anesthesiology, Critical Care, and Pain Management, Hospital for Special Surgery, New York, NY, USA; Departments of Anesthesiology and Healthcare Policy and Research, Weill Cornell Medical College, New York, NY, USA; Department of Anesthesiology, Perioperative Medicine and Intensive Care Medicine, Paracelsus Medical University, Salzburg, Austria. Electronic address: MemtsoudisS@HSS.EDU. 2. Department of Anesthesiology, Critical Care, and Pain Management, Hospital for Special Surgery, New York, NY, USA. 3. Institute for Healthcare Delivery Science, Department of Population Health Science and Policy, New York, NY, USA; Leni and Peter W. May Department of Orthopedics, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4. Department of Anesthesiology, Critical Care, and Pain Management, Hospital for Special Surgery, New York, NY, USA; Department of Anesthesiology, Perioperative Medicine and Intensive Care Medicine, Paracelsus Medical University, Salzburg, Austria. 5. Section of Surgical Pathophysiology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark; The Lundbeck Foundation Centre for Fast-track Hip and Knee Replacement, Copenhagen, Denmark.
Abstract
BACKGROUND: Enhanced recovery after surgery (ERAS) protocols have been shown to benefit recovery after several operations. However, large-scale data on the association between the level of ERAS use and perioperative complications are scarce, particularly in surgeries with increasing ERAS uptake, including total hip (THA) and knee arthroplasty (TKA). Using US national data, we examined the relationship between the number of ERAS components implemented ('level') and perioperative outcomes. METHODS: After ethics approval, we included 1 540 462 elective THA/TKA procedures (2006-2016, as recorded in the Premier Healthcare claims database) in this retrospective cohort study. Main outcomes were any complication, cardiopulmonary complications, mortality, blood transfusions, and length of stay. Eight commonly used ERAS components were included. Mixed-effects models measured associations between ERAS level and outcomes, with odds ratios (OR) and confidence intervals (CI) reported. RESULTS: ERAS use increased over time; overall, 21.6% (n=324 437), 62.7% (n=965 953), and 18.0% (n=250 072) of cases were classified as 'High', 'Medium', or 'Low' ERAS. 'High ERAS', 'Medium ERAS', and 'Low ERAS' level of use were defined as such if they received either >6, 5-6, or <5 ERAS components, respectively. After adjustment for relevant covariates, higher levels of ERAS use were associated with incremental reductions in 'any complication': 'Medium' vs 'Low' (OR=0.84; CI, 0.82-0.86) and 'High' vs 'Low' (OR=0.71; CI, 0.68-0.74). Similar patterns were found for the other study outcomes. Individual ERAS components with the strongest effect estimates were early physical therapy, avoidance of a urinary catheter, and tranexamic acid administration. CONCLUSIONS: ERAS components were used more frequently over time, and the level of utilisation was independently associated with incrementally improved complication odds and reduced length of stay during the primary admission. Possible indication bias limits the certainty of these findings.
BACKGROUND: Enhanced recovery after surgery (ERAS) protocols have been shown to benefit recovery after several operations. However, large-scale data on the association between the level of ERAS use and perioperative complications are scarce, particularly in surgeries with increasing ERAS uptake, including total hip (THA) and knee arthroplasty (TKA). Using US national data, we examined the relationship between the number of ERAS components implemented ('level') and perioperative outcomes. METHODS: After ethics approval, we included 1 540 462 elective THA/TKA procedures (2006-2016, as recorded in the Premier Healthcare claims database) in this retrospective cohort study. Main outcomes were any complication, cardiopulmonary complications, mortality, blood transfusions, and length of stay. Eight commonly used ERAS components were included. Mixed-effects models measured associations between ERAS level and outcomes, with odds ratios (OR) and confidence intervals (CI) reported. RESULTS: ERAS use increased over time; overall, 21.6% (n=324 437), 62.7% (n=965 953), and 18.0% (n=250 072) of cases were classified as 'High', 'Medium', or 'Low' ERAS. 'High ERAS', 'Medium ERAS', and 'Low ERAS' level of use were defined as such if they received either >6, 5-6, or <5 ERAS components, respectively. After adjustment for relevant covariates, higher levels of ERAS use were associated with incremental reductions in 'any complication': 'Medium' vs 'Low' (OR=0.84; CI, 0.82-0.86) and 'High' vs 'Low' (OR=0.71; CI, 0.68-0.74). Similar patterns were found for the other study outcomes. Individual ERAS components with the strongest effect estimates were early physical therapy, avoidance of a urinary catheter, and tranexamic acid administration. CONCLUSIONS: ERAS components were used more frequently over time, and the level of utilisation was independently associated with incrementally improved complication odds and reduced length of stay during the primary admission. Possible indication bias limits the certainty of these findings.
Authors: Kevin Berardino; Austin H Carroll; Daniel Popovsky; Robert Ricotti; Matthew D Civilette; William F Sherman; Alan D Kaye Journal: Orthop Rev (Pavia) Date: 2022-05-31
Authors: Jean-Yves Jenny; Cyril Courtin; Philippe Boisrenoult; Julien Chouteau; Pierre Henky; Claude Schwartz; Aymard de Ladoucette Journal: Int Orthop Date: 2020-06-30 Impact factor: 3.075
Authors: Derek J Roberts; Sudhir K Nagpal; Dalibor Kubelik; Timothy Brandys; Henry T Stelfox; Manoj M Lalu; Alan J Forster; Colin Jl McCartney; Daniel I McIsaac Journal: BMJ Date: 2020-11-25
Authors: Ulla Plenge; Romy Parker; Shamiela Davids; Gareth L Davies; Zahnne Fullerton; Lindsay Gray; Penelope Groenewald; Refqah Isaacs; Ntambue Kauta; Frederik M Louw; Andile Mazibuko; David M North; Marc Nortje; Glen M Nunes; Neo Pebane; Chantal Rajah; John Roos; Paul Ryan; Winlecia V September; Heidi Shanahan; Ruth E Siebritz; Rian W Smit; Simon Sombili; Alexandra Torborg; Johan F van der Merwe; Nico van der Westhuizen; Bruce Biccard Journal: BMC Musculoskelet Disord Date: 2020-11-05 Impact factor: 2.362